Scientists around the world are working to find a cure for the coronavirus. If the studies of Professor Didier Raoult on the use of chloroquine have been causing a stir for several days, other less media-based trials are being carried out all over the planet. Laurent Lagrost, director of research at Inserm, was one of the first to warn of the arrival of the coronavirus in France. He is currently working with Professor Didier Payen on a therapeutic solution capable of slowing down, even stopping, the epidemic.
>> LIVE - Coronavirus: follow the evolution of the situation
"Boost our immune system"
And the two scientists are on a track: the BCG vaccine, usually used against tuberculosis. "It is possible that this vaccine could boost our immune system," explains Laurent Lagrost. Because the exacerbated forms of Covid-19 come from an overly strong response from our immune defenses. According to him, the BCG vaccine could help our immune system to adapt and learn to fight against severe forms of infectious diseases.
>> PODCAST - Coronavirus: find all the answers to your questions here
To verify these hypotheses, Laurent Lagrost calls on French practitioners: he asks them to check the patient files, in order to determine the state of coverage by the BCG of patients admitted to intensive care. If verified, this track could also explain why the youngest are less affected by the Covid-19. "BCG vaccination against tuberculosis administered to children confers an immune memory between 15 to 20 years. While vaccination of adults sometimes dates back to 40 years ...", he points out.
> Paid leave, RTT, sick leave: what changes the state of health emergency
> What do we know about chloroquine, the treatment that is debating?
> What to do if you are sick, but not coronavirus?
> Why you will have to be patient to be reimbursed for a canceled trip
> Homemade bread, short circuits ... Our solutions to continue to eat well during confinement
> Sex: how to manage abstinence during confinement?
While waiting to conduct and have access to more observations, Laurent Lagrost remains cautious and evokes for the moment a "reasonable lead", which, if verified, could well "support and protect" the nursing staff.